This clinical trial is focused on studying treatments for a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) and a related condition known as T-cell Lymphoblastic Lymphoma (T-LL). The study involves several medications, including blinatumomab, isatuximab, and ponatinib. Blinatumomab, also known by its code names MT-103 and MEDI-538, is a type of protein that helps the immune system target cancer cells. Isatuximab, sometimes referred to as SAR650984, is another protein that targets specific markers on cancer cells. Ponatinib, also known as AP-24534, is a chemical compound that blocks certain proteins involved in cancer cell growth.
The purpose of this study is to explore how these new treatments can improve outcomes for adults with newly diagnosed ALL or T-LL. Participants will be divided into different groups to receive these treatments, sometimes in combination with a procedure called Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), which involves replacing diseased bone marrow with healthy cells from a donor. The study will follow participants over a period to observe the effects of these treatments on their health and cancer progression.
Throughout the study, participants will receive either the study medications or a placebo, and their health will be monitored regularly. The study aims to determine if these new treatments can help improve survival rates and reduce the risk of cancer returning. Participants will be closely observed for any side effects and overall quality of life during the treatment period. The study is expected to continue for several years to gather comprehensive data on the effectiveness and safety of these treatments.
Belgium 
France 
